ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1658

Cardiovascular Disease Risk and Risk Calculator Performance in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Abstract Number: 2284

Cardiovascular Outcomes in Diabetic Rheumatoid Arthritis Patients: TNF-α Inhibitors versus IL-6 Inhibitors
Abstract Number: 2317

Cardiovascular Risk and Psoriatic Arthritis Features: Dactylitis may Predict Cardiovascular Events
Abstract Number: 2568

Cardiovascular Risk Prediction in Systemic Lupus Erythematosus: Comparing the PREVENT and SLECRISK Models
Abstract Number: 2583

CCL20+ monocytes expanded by HLA-B*27 fuel Th17 generation in Axial Spondyloarthritis
Abstract Number: 0912

CD11c⁺CD21⁻ Autoimmune-Associated B Cells Derived from Double-Negative IgD⁻CD27⁻ Subsets Exhibit Enhanced IFNLR1 Expression in Systemic Lupus Erythematosus
Abstract Number: 0857

CD14-dependent MAP kinase signaling is required for pathogenic neutrophil extracellular trap formation in APS
Abstract Number: 2668

CD14⁺ Myeloid Cells Mediate UVB Photosensitivity in Autoimmune Skin Disease via a Spatially Resolved Inflammatory Circuit
Abstract Number: 1828

CD14+CXCL10+Monocytes Remodel the Peripheral Immune Network in sJIA via UBE2D1-Driven Inflammatory Programming
Abstract Number: 2465

CD19/BCMA Dual-Targeting FasTCAR-T Cells GC012F (AZD0120) in patients with refractory Systemic Lupus Erythematosusm: an open-label, single-center Phase I study
Abstract Number: 1005

CD49a Contributes to Binding and Survival of Synovial Resident Memory T cells
Abstract Number: 0015

CDR111 is a novel CD19 and BCMA dual-targeting T cell engager (TCE) for the treatment of severe and refractory autoimmune diseases
Abstract Number: 2073

Cell-free DNA as a Potential Marker of Muscle Involvement and Treatment Response in Myositis
Abstract Number: 2602

Cellular and molecular fine mapping in single-cell data pinpoints new immunopathology of systemic lupus erythematosus
Abstract Number: 1852

Cellular Landscape of Cutaneous Lupus Erythematosus Revealed by Single-Cell RNA Sequencing and Spatial Transcriptomics in the Lupus Accelerating Medicine Partnership Cohort

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].